Go Pro
→ Barricks gold output fell from 2 million ounces to 719000 (From Golden Portfolio) (Ad)tc pixel Free GMED Stock Alerts

Globus Medical (GMED) Financials

Globus Medical logo
$85.48 +0.33 (+0.39%)
As of 03:58 PM Eastern
Compare
Annual Income Statements for Globus Medical

Annual Income Statements for Globus Medical

This table shows Globus Medical's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 113 104 107 156 155 102 149 190 123 103 538
Consolidated Net Income / (Loss)		 113 104 107 156 155 102 149 190 123 103 538
Net Income / (Loss) Continuing Operations		 113 104 107 156 155 102 149 190 123 103 538
Total Pre-Tax Income 		173 157 170 189 190 126 180 243 165 121 605
Total Operating Income		 172 154 162 169 172 111 172 228 133 166 480
Total Gross Profit		 412 429 486 554 605 572 719 759 1,020 1,484 1,981
Total Revenue		 545 564 636 713 785 789 958 1,023 1,568 2,519 2,939
Operating Revenue		 545 564 636 713 785 789 958 1,023 1,568 2,519 2,939
Total Cost of Revenue		 132 135 150 159 180 217 239 264 548 1,035 958
Operating Cost of Revenue		 132 135 150 159 180 217 239 264 548 1,035 958
Total Operating Expenses		 240 275 324 384 433 460 547 531 887 1,318 1,501
Selling, General & Admin Expense		 210 222 268 312 355 355 408 432 644 981 1,178
Research & Development Expense		 36 45 44 55 60 85 97 73 124 164 147
Amortization Expense		 1.56 3.48 7.91 9.59 14 17 19 18 51 119 118
Restructuring Charge		 3.35 1.83 1.61 1.68 2.58 4.03 17 5.96 68 53 57
Total Other Income / (Expense), net		 1.17 3.14 8.09 19 18 14 8.45 15 32 -45 125
Interest & Investment Income		 - - - - - - - - 20 -4.19 7.14
Other Income / (Expense), net		 -0.14 0.08 1.48 6.00 0.55 0.51 -0.84 0.84 12 -41 118
Income Tax Expense		 60 53 63 32 35 24 31 53 43 18 67
Basic Earnings per Share		 $1.19 $1.09 $1.12 $1.60 $1.57 $1.04 $1.48 $1.89 $1.09 $0.76 $3.98
Weighted Average Basic Shares Outstanding		 95.05M 95.65M 96.24M 97.88M 99.15M 98.58M 100.73M 100.47M 113.09M 135.73M 135.22M
Diluted Earnings per Share		 $1.17 $1.08 $1.10 $1.54 $1.52 $1.01 $1.44 $1.85 $1.07 $0.75 $3.92
Weighted Average Diluted Shares Outstanding		 96.07M 96.43M 97.89M 101.32M 102.00M 100.97M 103.62M 102.64M 114.63M 137.86M 137.06M
Weighted Average Basic & Diluted Shares Outstanding		 94.80M 95.70M 95.80M 97.80M 99.84M 99.80M 101.56M 100.30M 135.37M 137.54M 135.25M

Quarterly Income Statements for Globus Medical

This table shows Globus Medical's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 15 -7.12 32 52 27 75 203 119 141 124 152
Consolidated Net Income / (Loss)		 15 -7.12 32 52 27 75 203 119 141 124 152
Net Income / (Loss) Continuing Operations		 15 -7.12 32 52 27 75 203 119 141 124 152
Total Pre-Tax Income 		25 -8.56 48 57 25 104 188 144 169 157 190
Total Operating Income		 10 8.00 50 48 60 97 76 137 169 150 182
Total Gross Profit		 351 365 370 355 394 403 497 517 565 526 548
Total Revenue		 617 607 630 626 657 598 745 769 826 760 790
Operating Revenue		 617 607 630 626 657 598 745 769 826 760 790
Total Cost of Revenue		 265 241 260 271 263 195 249 253 261 234 241
Operating Cost of Revenue		 265 241 260 271 263 195 249 253 261 234 241
Total Operating Expenses		 341 357 320 307 334 306 420 379 396 375 366
Selling, General & Admin Expense		 245 249 239 240 253 243 304 314 318 298 287
Research & Development Expense		 52 57 38 35 33 33 40 38 36 37 36
Amortization Expense		 28 30 30 30 30 29 30 30 29 30 30
Restructuring Charge		 16 22 13 1.57 17 1.06 47 -2.36 12 12 13
Total Other Income / (Expense), net		 15 -17 -2.04 8.93 -36 6.66 112 6.63 -0.11 6.69 7.39
Interest & Investment Income		 - - - - - 1.68 0.69 - - 5.43 7.07
Other Income / (Expense), net		 17 -15 0.29 9.71 -36 4.98 111 5.18 -3.42 1.25 0.31
Income Tax Expense		 9.96 -1.44 16 5.20 -1.84 28 -15 25 29 33 38
Basic Earnings per Share		 $0.02 ($0.05) $0.23 $0.38 $0.20 $0.55 $1.50 $0.88 $1.05 $0.92 $1.12
Weighted Average Basic Shares Outstanding		 113.09M 135.36M 135.20M 135.62M 135.73M 136.76M 135.21M 134.50M 135.22M 135.36M 135.05M
Diluted Earnings per Share		 $0.01 ($0.05) $0.23 $0.38 $0.19 $0.54 $1.49 $0.88 $1.01 $0.90 $1.10
Weighted Average Diluted Shares Outstanding		 114.63M 135.36M 136.98M 138.06M 137.86M 139.77M 136.50M 135.39M 137.06M 138.19M 137.38M
Weighted Average Basic & Diluted Shares Outstanding		 135.37M 135.06M 135.41M 136.17M 137.54M 135.38M 135.06M 133.84M 135.25M 135.74M 134.26M

Annual Cash Flow Statements for Globus Medical

This table details how cash moves in and out of Globus Medical's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 -25 -16 51 21 56 44 -46 -43 315 317 -281
Net Cash From Operating Activities		 124 148 159 182 172 199 276 178 243 521 753
Net Cash From Continuing Operating Activities		 124 148 159 182 172 199 276 178 243 521 753
Net Income / (Loss) Continuing Operations		 113 104 107 156 155 102 149 190 123 103 538
Consolidated Net Income / (Loss)		 113 104 107 156 155 102 149 190 123 103 538
Depreciation Expense		 24 39 42 42 53 63 70 68 146 253 277
Amortization Expense		 3.35 4.07 2.67 1.68 -1.09 0.59 2.78 5.39 80 242 26
Non-Cash Adjustments To Reconcile Net Income		 9.87 24 28 30 32 72 72 37 52 119 -53
Changes in Operating Assets and Liabilities, net		 -26 -23 -21 -48 -67 -39 -18 -122 -157 -197 -35
Net Cash From Investing Activities		 -153 -163 -111 -193 -140 -117 -376 -110 303 -176 -355
Net Cash From Continuing Investing Activities		 -153 -163 -111 -193 -140 -117 -376 -110 303 -176 -355
Purchase of Property, Plant & Equipment		 -51 -41 -51 -60 -71 -64 -57 -74 -78 -115 -165
Acquisitions		 -49 -76 -30 -15 -24 -33 -34 -31 -296 -18 -262
Purchase of Investments		 -300 -350 -393 -538 -347 -224 -622 -420 -101 -114 -108
Sale and/or Maturity of Investments		 246 335 363 384 301 203 338 415 778 71 179
Net Cash From Financing Activities		 4.28 0.47 1.63 33 24 -39 54 -110 -232 -28 -679
Net Cash From Continuing Financing Activities		 4.28 0.47 1.63 33 24 -39 54 -110 -232 -28 -679
Repayment of Debt		 - - - - - - - - 0.00 0.00 -450
Repurchase of Common Equity		 - - - 0.00 0.00 -105 0.00 -144 -226 -86 -300
Other Financing Activities, net		 4.28 0.47 1.63 33 24 66 54 35 -6.26 58 71
Cash Income Taxes Paid		 57 50 59 31 34 25 45 78 101 159 99

Quarterly Cash Flow Statements for Globus Medical

This table details how cash moves in and out of Globus Medical's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 188 -113 56 212 162 -323 -232 142 132 35 -53
Net Cash From Operating Activities		 105 52 54 204 210 177 78 250 249 202 210
Net Cash From Continuing Operating Activities		 105 52 54 204 210 177 78 250 249 202 210
Net Income / (Loss) Continuing Operations		 15 -7.12 32 52 27 75 203 119 141 124 152
Consolidated Net Income / (Loss)		 15 -7.12 32 52 27 75 203 119 141 124 152
Depreciation Expense		 71 55 64 67 68 66 71 71 69 70 69
Non-Cash Adjustments To Reconcile Net Income		 1.84 32 23 14 50 19 -108 12 25 22 26
Changes in Operating Assets and Liabilities, net		 -44 -88 -124 3.28 12 10 -93 41 7.39 -14 -38
Net Cash From Investing Activities		 321 -47 -10 -15 -104 131 -299 -76 -111 -183 -129
Net Cash From Continuing Investing Activities		 321 -47 -10 -15 -104 131 -299 -76 -111 -183 -129
Purchase of Property, Plant & Equipment		 -23 -29 -28 -42 -17 -36 -47 -36 -46 -40 -33
Acquisitions		 - -13 -4.89 -0.10 - -5.00 -253 -4.67 -0.08 -4.91 -1.50
Purchase of Investments		 - -8.02 -4.16 -1.19 -100 -1.75 - -35 -70 -146 -108
Sale and/or Maturity of Investments		 343 2.65 26 28 13 174 - - 5.25 8.24 13
Net Cash From Financing Activities		 -237 -116 8.71 20 60 -635 -25 -32 13 18 -134
Net Cash From Continuing Financing Activities		 -237 -116 8.71 20 60 -635 -25 -32 13 18 -134
Repurchase of Common Equity		 -226 -83 -1.47 - -1.00 -190 -25 -40 -45 0.00 -136
Other Financing Activities, net		 -12 -32 10 20 61 5.04 0.06 7.96 58 18 1.56
Effect of Exchange Rate Changes		 -0.35 -3.31 3.77 4.07 -4.28 3.54 14 0.51 - -3.09 0.60
Cash Income Taxes Paid		 35 1.97 70 46 41 7.20 86 1.87 3.82 5.99 25

Annual Balance Sheets for Globus Medical

This table presents Globus Medical's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 834 928 1,079 1,301 1,532 1,679 1,957 2,076 5,086 5,252 5,303
Total Current Assets		 545 514 620 631 687 822 865 983 1,915 2,177 2,126
Cash & Equivalents		 60 67 - - - - 193 150 467 784 526
Short-Term Investments		 221 223 255 200 116 187 250 296 50 106 31
Accounts Receivable		 78 92 117 137 154 142 164 213 503 558 679
Inventories, net		 105 113 108 131 196 229 237 299 848 659 759
Prepaid Expenses		 7.35 15 11 15 17 18 18 21 45 50 65
Current Deferred & Refundable Income Taxes		 47 3.80 8.72 7.29 8.10 6.42 1.22 4.06 1.64 21 65
Plant, Property, & Equipment, net		 115 124 143 172 200 217 221 244 587 562 564
Total Noncurrent Assets		 175 290 315 498 645 641 872 849 2,584 2,513 2,613
Long-Term Investments		 49 60 56 263 410 359 562 496 75 66 72
Goodwill		 92 106 124 124 129 157 180 197 1,435 1,432 1,435
Intangible Assets		 33 62 79 87 79 87 69 64 925 795 745
Noncurrent Deferred & Refundable Income Taxes		 0.00 31 20 14 5.93 6.62 24 49 11 94 218
Other Noncurrent Operating Assets		 0.59 0.93 7.95 10 22 32 36 43 139 125 143
Total Liabilities & Shareholders' Equity		 834 928 1,079 1,301 1,532 1,679 1,957 2,076 5,086 5,252 5,303
Total Liabilities		 119 96 111 115 130 173 216 230 1,088 1,074 730
Total Current Liabilities		 83 80 93 96 111 121 140 159 392 856 498
Accounts Payable		 16 17 25 26 25 18 22 36 57 75 99
Accrued Expenses		 54 46 53 60 63 78 91 92 240 261 334
Current Deferred Revenue		 - 0.00 0.76 2.60 5.40 8.13 12 14 18 22 28
Current Deferred & Payable Income Tax Liabilities		 0.76 1.91 3.27 0.92 1.06 1.10 1.05 0.99 3.85 11 4.16
Other Current Liabilities		 12 14 11 6.83 17 15 14 16 73 44 34
Total Noncurrent Liabilities		 36 16 18 19 18 52 76 71 696 219 231
Noncurrent Deferred & Payable Income Tax Liabilities		 13 7.88 11 8.11 6.02 6.20 4.31 1.78 84 24 24
Other Noncurrent Operating Liabilities		 23 7.79 6.98 11 12 46 71 69 194 195 207
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 715 832 968 1,186 1,402 1,506 1,741 1,846 3,998 4,177 4,573
Total Preferred & Common Equity		 715 832 968 1,186 1,402 1,506 1,741 1,846 3,998 4,177 4,573
Total Common Equity		 715 832 968 1,186 1,402 1,506 1,741 1,846 3,998 4,177 4,573
Common Stock		 193 212 238 300 357 457 554 631 2,871 3,031 3,170
Retained Earnings		 525 629 736 893 1,048 1,045 1,194 1,240 1,137 1,153 1,388
Accumulated Other Comprehensive Income / (Loss)		 -1.96 -8.64 -6.91 -7.17 -2.90 3.96 -6.77 -25 -10 -6.86 15

Quarterly Balance Sheets for Globus Medical

This table presents Globus Medical's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 2,150 2,212 5,356 4,944 4,994 5,086 4,711 4,961 5,096 5,440 5,488
Total Current Assets		 1,070 1,210 1,917 1,829 1,924 2,057 1,710 1,730 1,924 2,198 2,216
Cash & Equivalents		 218 306 280 354 410 623 461 229 372 561 508
Short-Term Investments		 287 306 189 80 83 72 0.00 0.00 19 69 87
Accounts Receivable		 223 240 494 534 612 588 535 612 619 686 692
Inventories, net		 321 336 905 816 770 718 664 772 772 773 811
Prepaid Expenses		 19 20 48 43 46 51 47 68 74 60 70
Current Deferred & Refundable Income Taxes		 3.04 1.76 1.74 0.37 2.50 5.15 3.02 49 69 49 47
Plant, Property, & Equipment, net		 245 248 607 579 572 568 556 588 578 557 534
Total Noncurrent Assets		 834 754 2,832 2,536 2,498 2,462 2,445 2,644 2,593 2,684 2,739
Long-Term Investments		 480 392 276 51 28 12 0.00 0.00 17 169 245
Goodwill		 199 199 1,122 1,451 1,454 1,432 1,433 1,435 1,434 1,439 1,438
Intangible Assets		 59 55 1,262 888 867 843 772 796 774 721 693
Noncurrent Deferred & Refundable Income Taxes		 51 62 7.32 11 18 45 117 276 232 215 225
Other Noncurrent Operating Assets		 45 47 164 135 131 129 123 136 136 140 138
Total Liabilities & Shareholders' Equity		 2,150 2,212 5,356 4,944 4,994 5,086 4,711 4,961 5,096 5,440 5,488
Total Liabilities		 235 227 1,169 1,021 1,017 1,017 623 665 697 707 720
Total Current Liabilities		 168 155 429 786 794 818 385 425 466 482 479
Accounts Payable		 40 34 87 50 67 58 73 87 87 104 107
Accrued Expenses		 84 90 222 210 216 255 238 282 326 313 301
Current Deferred Revenue		 14 15 18 17 20 21 17 24 18 26 28
Current Deferred & Payable Income Tax Liabilities		 16 1.76 34 43 11 4.17 13 0.00 1.29 3.03 6.04
Other Current Liabilities		 14 15 68 42 49 43 44 32 33 36 38
Total Noncurrent Liabilities		 67 72 740 235 223 199 238 241 231 225 240
Noncurrent Deferred & Payable Income Tax Liabilities		 1.37 5.30 132 40 27 7.48 47 24 23 25 42
Other Noncurrent Operating Liabilities		 66 67 198 195 196 191 192 216 208 200 198
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 1,915 1,985 4,187 3,922 3,976 4,069 4,088 4,296 4,399 4,732 4,769
Total Preferred & Common Equity		 1,915 1,985 4,187 3,922 3,976 4,069 4,088 4,296 4,399 4,732 4,769
Total Common Equity		 1,915 1,985 4,187 3,922 3,976 4,069 4,088 4,296 4,399 4,732 4,769
Common Stock		 645 657 2,858 2,887 2,914 2,950 3,054 3,072 3,095 3,206 3,230
Retained Earnings		 1,289 1,347 1,348 1,047 1,074 1,126 1,036 1,214 1,292 1,512 1,527
Accumulated Other Comprehensive Income / (Loss)		 -19 -19 -19 -11 -12 -6.96 -2.17 10 11 14 11

Annual Metrics And Ratios for Globus Medical

This table displays calculated financial ratios and metrics derived from Globus Medical's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 14.84% 3.53% 12.76% 12.11% 10.15% 0.47% 21.43% 6.76% 53.34% 60.62% 16.65%
EBITDA Growth		 22.74% -1.23% 5.58% 5.08% 2.54% -21.76% 38.97% 24.07% 22.55% 67.38% 45.22%
EBIT Growth		 24.59% -10.38% 5.90% 7.35% -1.59% -35.12% 52.85% 33.71% -36.51% -14.01% 378.68%
NOPAT Growth		 21.78% -9.02% -0.02% 37.40% 0.04% -35.58% 57.07% 25.44% -44.55% 43.16% 201.22%
Net Income Growth		 21.95% -7.49% 2.88% 45.76% -0.81% -34.10% 45.86% 27.47% -35.39% -16.19% 422.28%
EPS Growth		 20.62% -7.69% 1.85% 40.00% -1.30% -33.55% 42.57% 28.47% -42.16% -29.91% 422.67%
Operating Cash Flow Growth		 56.63% 19.21% 7.60% 14.20% -5.32% 15.59% 38.98% -35.40% 36.44% 113.82% 44.72%
Free Cash Flow Firm Growth		 -64.64% -273.93% 335.48% 111.98% -56.32% 21.89% 150.77% -92.66% -30,147.99% 110.62% -50.93%
Invested Capital Growth		 39.29% 33.79% 11.87% 8.32% 16.94% 5.81% 2.00% 22.98% 322.59% -4.12% 7.63%
Revenue Q/Q Growth		 2.60% 1.62% 4.00% 2.87% 2.04% 2.84% 1.76% 2.45% 27.89% 1.64% 6.11%
EBITDA Q/Q Growth		 9.84% -4.96% 1.91% -0.99% 4.03% 7.86% -14.40% 14.90% 29.58% -2.21% 11.97%
EBIT Q/Q Growth		 10.79% -12.03% 8.96% -2.92% 3.94% 9.24% -19.55% 20.68% -16.89% -2.90% 31.17%
NOPAT Q/Q Growth		 9.45% -11.77% -0.47% 7.07% 6.35% 9.64% -20.23% 20.08% -28.35% 61.69% 25.01%
Net Income Q/Q Growth		 9.69% -11.31% 0.07% 8.59% 6.00% 7.83% -20.24% 22.52% -22.18% 12.53% 26.92%
EPS Q/Q Growth		 8.33% -10.74% 0.00% 7.69% 4.83% 10.99% -20.88% 21.71% -30.52% 31.58% 26.45%
Operating Cash Flow Q/Q Growth		 55.35% -11.81% 13.16% -0.30% 6.19% 14.96% -1.40% -6.44% 20.07% 25.46% 5.35%
Free Cash Flow Firm Q/Q Growth		 129.26% 16.51% -11.95% 35.90% -16.74% 59.00% -27.80% -65.20% 1.41% 113.52% -1.52%
Invested Capital Q/Q Growth		 3.16% -1.32% -0.15% -2.80% 0.00% -1.50% 0.30% 5.80% -0.78% -3.55% -1.19%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 75.71% 76.12% 76.34% 77.64% 77.08% 72.44% 75.03% 74.22% 65.05% 58.90% 67.41%
EBITDA Margin		 36.63% 34.94% 32.71% 30.67% 28.55% 22.23% 25.44% 29.57% 23.63% 24.62% 30.65%
Operating Margin		 31.61% 27.33% 25.45% 23.75% 21.90% 14.12% 17.95% 22.29% 8.49% 6.59% 16.33%
EBIT Margin		 31.59% 27.34% 25.68% 24.59% 21.97% 14.19% 17.86% 22.37% 9.26% 4.96% 20.35%
Profit (Net Income) Margin		 20.70% 18.50% 16.88% 21.95% 19.76% 12.96% 15.57% 18.59% 7.83% 4.09% 18.30%
Tax Burden Percent		 65.27% 66.34% 63.17% 82.96% 81.71% 81.24% 82.70% 78.25% 74.29% 85.31% 88.89%
Interest Burden Percent		 100.42% 101.98% 104.05% 107.57% 110.09% 112.46% 105.43% 106.22% 113.86% 96.65% 101.19%
Effective Tax Rate		 34.73% 33.66% 36.83% 17.04% 18.29% 18.76% 17.30% 21.75% 25.71% 14.69% 11.11%
Return on Invested Capital (ROIC)		 36.41% 24.34% 20.07% 25.07% 22.23% 12.91% 19.53% 21.75% 4.19% 3.78% 11.21%
ROIC Less NNEP Spread (ROIC-NNEP)		 36.30% 23.75% 18.76% 21.97% 20.02% 11.35% 18.75% 20.54% -0.10% 15.00% -8.29%
Return on Net Nonoperating Assets (RNNOA)		 -19.07% -10.85% -8.14% -10.54% -10.24% -5.88% -10.34% -11.15% 0.02% -1.26% 1.08%
Return on Equity (ROE)		 17.34% 13.49% 11.93% 14.53% 11.99% 7.03% 9.19% 10.60% 4.20% 2.52% 12.29%
Cash Return on Invested Capital (CROIC)		 3.57% -4.56% 8.86% 17.08% 6.61% 7.27% 17.54% 1.14% -119.27% 7.99% 3.86%
Operating Return on Assets (OROA)		 22.38% 17.51% 16.28% 14.74% 12.18% 6.97% 9.41% 11.34% 4.06% 2.42% 11.33%
Return on Assets (ROA)		 14.67% 11.85% 10.70% 13.15% 10.96% 6.37% 8.20% 9.43% 3.43% 1.99% 10.19%
Return on Common Equity (ROCE)		 17.34% 13.48% 11.93% 14.53% 11.99% 7.03% 9.19% 10.60% 4.20% 2.52% 12.29%
Return on Equity Simple (ROE_SIMPLE)		 15.77% 12.54% 11.09% 13.20% 11.07% 6.79% 8.57% 10.30% 3.07% 2.47% 0.00%
Net Operating Profit after Tax (NOPAT)		 112 102 102 140 141 91 142 178 99 142 427
NOPAT Margin		 20.63% 18.13% 16.08% 19.70% 17.89% 11.47% 14.84% 17.44% 6.31% 5.62% 14.51%
Net Nonoperating Expense Percent (NNEP)		 0.11% 0.59% 1.31% 3.10% 2.22% 1.56% 0.78% 1.21% 4.29% -11.22% 19.50%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - 9.66% 2.24% 3.06% 9.33%
Cost of Revenue to Revenue		 24.29% 23.88% 23.66% 22.36% 22.92% 27.56% 24.97% 25.78% 34.95% 41.10% 32.59%
SG&A Expenses to Revenue		 38.59% 39.39% 42.11% 43.70% 45.17% 44.96% 42.60% 42.25% 41.02% 38.94% 40.10%
R&D to Revenue		 6.67% 7.90% 6.87% 7.78% 7.65% 10.71% 10.16% 7.14% 7.91% 6.50% 5.01%
Operating Expenses to Revenue		 44.09% 48.79% 50.90% 53.89% 55.18% 58.32% 57.08% 51.93% 56.56% 52.31% 51.08%
Earnings before Interest and Taxes (EBIT)		 172 154 163 175 173 112 171 229 145 125 598
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 200 197 208 219 224 175 244 302 371 620 901
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.70 2.86 4.09 3.60 4.17 4.27 4.21 4.02 1.84 2.70 2.56
Price to Tangible Book Value (P/TBV)		 4.49 3.58 5.18 4.37 4.90 5.10 4.91 4.68 4.48 5.78 4.88
Price to Revenue (P/Rev)		 4.86 4.22 6.23 5.98 7.45 8.16 7.65 7.25 4.68 4.47 3.98
Price to Earnings (P/E)		 23.49 22.79 36.90 27.24 37.71 62.92 49.11 38.99 59.76 109.36 21.73
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 4.26% 4.39% 2.71% 3.67% 2.65% 1.59% 2.04% 2.56% 1.67% 0.91% 4.60%
Enterprise Value to Invested Capital (EV/IC)		 6.38 4.21 6.56 6.28 7.53 7.84 8.59 7.16 1.88 2.93 2.80
Enterprise Value to Revenue (EV/Rev)		 4.21 3.59 5.55 5.13 6.53 7.16 6.60 6.33 4.57 4.27 3.76
Enterprise Value to EBITDA (EV/EBITDA)		 11.50 10.28 16.97 16.74 22.89 32.21 25.93 21.40 19.34 17.33 12.27
Enterprise Value to EBIT (EV/EBIT)		 13.33 13.14 21.62 20.87 29.75 50.47 36.94 28.29 49.34 86.06 18.49
Enterprise Value to NOPAT (EV/NOPAT)		 20.40 19.81 34.54 26.05 36.52 62.41 44.45 36.29 72.46 75.91 25.92
Enterprise Value to Operating Cash Flow (EV/OCF)		 18.50 13.71 22.20 20.15 29.84 28.42 22.88 36.27 29.43 20.65 14.67
Enterprise Value to Free Cash Flow (EV/FCFF)		 208.08 0.00 78.22 38.24 122.78 110.90 49.47 690.06 0.00 35.92 75.30
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.11 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.10 0.00 0.00
Financial Leverage		 -0.53 -0.46 -0.43 -0.48 -0.51 -0.52 -0.55 -0.54 -0.19 -0.08 -0.13
Leverage Ratio		 1.18 1.14 1.11 1.10 1.09 1.10 1.12 1.12 1.23 1.26 1.21
Compound Leverage Factor		 1.19 1.16 1.16 1.19 1.21 1.24 1.18 1.19 1.40 1.22 1.22
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 9.45% 9.59% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 9.59% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 9.45% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 99.99% 99.99% 99.99% 100.00% 100.00% 99.99% 100.00% 100.00% 90.55% 90.41% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.13 0.71 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.47 -0.83 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.13 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.22 3.13 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -1.78 -3.62 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 4.22 0.00 0.00
Altman Z-Score		 16.26 17.59 24.10 24.66 29.39 24.36 22.44 21.53 5.12 7.46 11.27
Noncontrolling Interest Sharing Ratio		 0.01% 0.01% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 6.59 6.43 6.67 6.56 6.17 6.80 6.17 6.18 4.88 2.54 4.26
Quick Ratio		 4.34 4.79 4.01 3.51 2.42 2.72 4.34 4.14 2.60 1.69 2.48
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 11 -19 45 96 42 51 128 9.38 -2,819 299 147
Operating Cash Flow to CapEx		 244.30% 361.35% 310.04% 332.09% 243.07% 312.28% 485.56% 241.02% 311.09% 451.05% 457.52%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 71.44 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 124.29 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 96.73 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.71 0.64 0.63 0.60 0.55 0.49 0.53 0.51 0.44 0.49 0.56
Accounts Receivable Turnover		 7.12 6.65 6.10 5.62 5.39 5.33 6.26 5.42 4.38 4.75 4.75
Inventory Turnover		 1.35 1.24 1.36 1.33 1.10 1.02 1.03 0.98 0.96 1.37 1.35
Fixed Asset Turnover		 5.91 4.72 4.76 4.53 4.23 3.79 4.38 4.40 3.78 4.39 5.22
Accounts Payable Turnover		 7.11 8.06 7.08 6.26 7.13 10.16 11.91 9.09 11.82 15.71 11.01
Days Sales Outstanding (DSO)		 51.29 54.90 59.88 64.95 67.71 68.46 58.31 67.39 83.37 76.85 76.79
Days Inventory Outstanding (DIO)		 270.59 295.28 268.20 274.38 332.16 357.06 355.62 370.90 381.90 265.67 270.28
Days Payable Outstanding (DPO)		 51.35 45.31 51.57 58.31 51.22 35.93 30.64 40.18 30.89 23.23 33.15
Cash Conversion Cycle (CCC)		 270.53 304.88 276.51 281.02 348.66 389.59 383.29 398.12 434.38 319.29 313.93
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 359 481 538 583 681 721 735 904 3,822 3,664 3,944
Invested Capital Turnover		 1.76 1.34 1.25 1.27 1.24 1.13 1.32 1.25 0.66 0.67 0.77
Increase / (Decrease) in Invested Capital		 101 121 57 45 99 40 14 169 2,918 -158 280
Enterprise Value (EV)		 2,294 2,026 3,531 3,659 5,132 5,650 6,320 6,473 7,167 10,750 11,056
Market Capitalization		 2,649 2,377 3,961 4,262 5,853 6,436 7,326 7,415 7,343 11,262 11,685
Book Value per Share		 $7.51 $8.68 $10.04 $12.04 $14.11 $15.26 $17.16 $18.49 $29.01 $30.68 $34.17
Tangible Book Value per Share		 $6.20 $6.93 $7.94 $9.89 $12.02 $12.79 $14.71 $15.88 $11.89 $14.32 $17.88
Total Capital		 715 832 968 1,186 1,402 1,506 1,741 1,846 4,415 4,621 4,573
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 417 443 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 417 0.00 0.00
Net Debt		 -356 -351 -430 -603 -721 -785 -1,006 -942 -176 -513 -629
Capital Expenditures (CapEx)		 51 41 51 55 71 64 57 74 78 115 165
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 155 143 154 195 265 274 281 378 1,005 875 1,070
Debt-free Net Working Capital (DFNWC)		 462 434 527 535 576 701 724 824 1,523 1,765 1,627
Net Working Capital (NWC)		 462 434 527 535 576 701 724 824 1,523 1,321 1,627
Net Nonoperating Expense (NNE)		 -0.38 -2.08 -5.11 -16 -15 -12 -6.99 -12 -24 39 -111
Net Nonoperating Obligations (NNO)		 -356 -351 -430 -603 -721 -785 -1,006 -942 -176 -513 -629
Total Depreciation and Amortization (D&A)		 27 43 45 43 52 63 73 74 225 495 303
Debt-free, Cash-free Net Working Capital to Revenue		 28.45% 25.37% 24.15% 27.33% 33.69% 34.76% 29.32% 36.96% 64.09% 34.72% 36.40%
Debt-free Net Working Capital to Revenue		 84.83% 76.93% 82.91% 74.98% 73.35% 88.84% 75.60% 80.57% 97.10% 70.05% 55.36%
Net Working Capital to Revenue		 84.83% 76.93% 82.91% 74.98% 73.35% 88.84% 75.60% 80.57% 97.10% 52.45% 55.36%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $1.19 $1.09 $1.12 $1.60 $1.57 $1.04 $1.48 $1.89 $1.09 $0.76 $3.98
Adjusted Weighted Average Basic Shares Outstanding		 95.05M 95.65M 96.24M 97.88M 99.15M 98.58M 100.73M 100.47M 113.09M 135.73M 135.22M
Adjusted Diluted Earnings per Share		 $1.17 $1.08 $1.10 $1.54 $1.52 $1.01 $1.44 $1.85 $1.07 $0.75 $3.92
Adjusted Weighted Average Diluted Shares Outstanding		 96.07M 96.43M 97.89M 101.32M 102.00M 100.97M 103.62M 102.64M 114.63M 137.86M 137.06M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 95.37M 95.97M 96.73M 98.65M 99.84M 99.80M 101.56M 100.30M 135.37M 137.54M 135.25M
Normalized Net Operating Profit after Tax (NOPAT)		 107 106 105 147 144 94 161 185 150 187 478
Normalized NOPAT Margin		 19.69% 18.72% 16.50% 20.58% 18.39% 11.89% 16.82% 18.07% 9.56% 7.44% 16.25%
Pre Tax Income Margin		 31.72% 27.89% 26.72% 26.45% 24.19% 15.96% 18.83% 23.76% 10.54% 4.79% 20.59%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 29.82 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 33.80 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.26 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 6.25 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 102.33% 0.00% 75.98% 183.57% 83.30% 55.86%

Quarterly Metrics And Ratios for Globus Medical

This table displays calculated financial ratios and metrics derived from Globus Medical's official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 135,253,051.00 135,744,626.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 135,253,051.00 135,744,626.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - 0.92 1.12
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 124.60% 119.26% 115.93% 63.10% 6.61% -1.41% 18.37% 22.91% 25.73% 27.04% 5.94%
EBITDA Growth		 112.89% 44.72% 105.04% 276.51% -8.79% 60.03% 51.95% 14.84% 66.20% 27.04% -4.48%
EBIT Growth		 -51.71% -111.75% -24.80% 1,173.48% -13.50% 1,630.42% 275.59% 146.58% 595.63% 48.69% -2.53%
NOPAT Growth		 -86.02% -87.23% -35.27% 27,385.65% 963.68% 1,161.39% 147.70% 159.60% 117.22% 68.54% 77.55%
Net Income Growth		 -69.97% -114.49% -44.97% 5,093.99% 76.30% 1,160.31% 538.68% 129.50% 430.44% 64.72% -25.28%
EPS Growth		 -97.92% -110.42% -59.65% 3,700.00% 1,800.00% 1,180.00% 547.83% 131.58% 431.58% 66.67% -26.17%
Operating Cash Flow Growth		 63.62% -1.74% 54.90% 303.40% 100.95% 238.44% 43.51% 22.61% 18.18% 14.14% 169.36%
Free Cash Flow Firm Growth		 -2,220.88% -2,309.60% -2,461.71% 103.21% 107.64% 110.41% 96.59% -181.62% -162.50% -161.48% 389.39%
Invested Capital Growth		 322.59% 314.94% 296.25% -1.37% -4.12% -6.06% 4.63% 5.06% 7.63% 8.44% -3.40%
Revenue Q/Q Growth		 60.71% -1.60% 3.80% -0.63% 5.05% -9.00% 24.61% 3.18% 7.46% -8.05% 3.92%
EBITDA Q/Q Growth		 212.80% -31.72% 59.52% 10.51% -24.22% 19.79% 51.47% -16.48% 9.66% -8.43% 13.88%
EBIT Q/Q Growth		 612.09% -124.17% 849.04% 15.81% -58.74% 327.58% 83.83% -23.97% 16.40% -8.61% 20.51%
NOPAT Q/Q Growth		 3,728.22% -8.06% 491.69% 31.98% 48.15% 9.03% 16.19% 38.33% 23.96% -15.40% 22.40%
Net Income Q/Q Growth		 1,406.41% -147.34% 546.26% 63.21% -48.87% 184.71% 168.81% -41.35% 18.18% -11.59% 21.94%
EPS Q/Q Growth		 0.00% -600.00% 560.00% 65.22% -50.00% 184.21% 175.93% -40.94% 14.77% -10.89% 22.22%
Operating Cash Flow Q/Q Growth		 107.34% -49.95% 3.57% 275.34% 3.28% -15.71% -56.08% 220.68% -0.44% -18.59% 3.65%
Free Cash Flow Firm Q/Q Growth		 2.85% -0.45% 1.79% 103.35% 130.97% 36.90% -132.21% 19.86% -76.87% -34.67% 251.60%
Invested Capital Q/Q Growth		 -0.78% 1.01% 0.66% -2.23% -3.55% -1.03% 12.12% -1.84% -1.19% -0.28% -0.13%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 56.94% 60.19% 58.70% 56.77% 59.92% 67.33% 66.62% 67.16% 68.41% 69.20% 69.42%
EBITDA Margin		 25.88% 17.96% 27.60% 30.70% 22.14% 29.15% 35.43% 28.68% 29.27% 29.15% 31.95%
Operating Margin		 1.64% 1.32% 7.88% 7.69% 9.17% 16.22% 10.21% 17.86% 20.49% 19.79% 23.10%
EBIT Margin		 4.47% -1.10% 7.93% 9.24% 3.63% 17.05% 25.15% 18.53% 20.08% 19.96% 23.14%
Profit (Net Income) Margin		 2.44% -1.17% 5.04% 8.28% 4.03% 12.62% 27.22% 15.47% 17.01% 16.36% 19.20%
Tax Burden Percent		 60.15% 83.16% 66.75% 90.89% 107.45% 72.79% 107.80% 82.62% 83.08% 79.14% 79.85%
Interest Burden Percent		 90.64% 128.42% 95.32% 98.66% 103.42% 101.65% 100.37% 101.02% 102.00% 103.58% 103.87%
Effective Tax Rate		 39.85% 0.00% 33.25% 9.11% -7.45% 27.21% -7.80% 17.38% 16.92% 20.86% 20.15%
Return on Invested Capital (ROIC)		 0.66% 0.73% 4.83% 4.53% 6.63% 7.92% 7.27% 10.49% 13.15% 12.85% 14.52%
ROIC Less NNEP Spread (ROIC-NNEP)		 -0.95% 3.16% 5.08% 1.84% 17.74% 6.06% -68.30% 8.87% 13.17% 12.01% 13.41%
Return on Net Nonoperating Assets (RNNOA)		 0.18% -0.57% -0.93% -0.14% -1.49% -0.40% 2.64% -0.71% -1.72% -1.72% -1.58%
Return on Equity (ROE)		 0.84% 0.16% 3.90% 4.39% 5.14% 7.52% 9.91% 9.78% 11.43% 11.13% 12.93%
Cash Return on Invested Capital (CROIC)		 -119.27% -119.80% -117.68% 3.66% 7.99% 11.67% 2.23% 3.83% 3.86% 4.47% 16.43%
Operating Return on Assets (OROA)		 1.96% -0.59% 4.92% 4.39% 1.77% 8.87% 13.27% 10.08% 11.18% 12.19% 13.93%
Return on Assets (ROA)		 1.07% -0.63% 3.13% 3.93% 1.97% 6.56% 14.36% 8.42% 9.47% 9.99% 11.55%
Return on Common Equity (ROCE)		 0.84% 0.16% 3.90% 4.39% 5.14% 7.52% 9.91% 9.78% 11.43% 11.13% 12.93%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 1.70% 1.02% 2.25% 0.00% 4.54% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 6.09 5.60 33 44 65 71 82 113 141 119 146
NOPAT Margin		 0.99% 0.92% 5.26% 6.99% 9.85% 11.81% 11.01% 14.76% 17.02% 15.66% 18.45%
Net Nonoperating Expense Percent (NNEP)		 1.60% -2.43% -0.25% 2.68% -11.11% 1.86% 75.57% 1.62% -0.02% 0.84% 1.10%
Return On Investment Capital (ROIC_SIMPLE)		 0.14% - - - 1.40% 1.73% 1.91% 2.58% 3.08% 2.51% 3.05%
Cost of Revenue to Revenue		 43.06% 39.81% 41.30% 43.23% 40.08% 32.67% 33.38% 32.84% 31.60% 30.80% 30.58%
SG&A Expenses to Revenue		 39.69% 41.00% 37.82% 38.47% 38.56% 40.59% 40.74% 40.78% 38.54% 39.19% 36.32%
R&D to Revenue		 8.48% 9.44% 5.99% 5.65% 5.08% 5.53% 5.36% 4.95% 4.38% 4.80% 4.60%
Operating Expenses to Revenue		 55.30% 58.88% 50.82% 49.08% 50.75% 51.11% 56.41% 49.30% 47.91% 49.40% 46.32%
Earnings before Interest and Taxes (EBIT)		 28 -6.66 50 58 24 102 187 143 166 152 183
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 160 109 174 192 146 174 264 221 242 221 252
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 1.84 1.88 2.33 2.38 2.70 2.46 1.86 1.76 2.56 2.46 2.25
Price to Tangible Book Value (P/TBV)		 4.48 4.67 5.59 5.40 5.78 5.35 3.87 3.53 4.88 4.53 4.07
Price to Revenue (P/Rev)		 4.68 3.89 4.14 3.91 4.47 4.01 3.04 2.79 3.98 3.76 3.41
Price to Earnings (P/E)		 59.76 110.93 227.41 105.85 109.36 54.26 22.40 18.25 21.73 19.86 20.03
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 1.67% 0.90% 0.44% 0.94% 0.91% 1.84% 4.46% 5.48% 4.60% 5.03% 4.99%
Enterprise Value to Invested Capital (EV/IC)		 1.88 1.90 2.36 2.48 2.93 2.65 1.91 1.84 2.80 2.76 2.52
Enterprise Value to Revenue (EV/Rev)		 4.57 3.86 4.10 3.80 4.27 3.83 2.95 2.65 3.76 3.50 3.14
Enterprise Value to EBITDA (EV/EBITDA)		 19.34 18.13 18.57 14.84 17.33 14.01 10.00 9.11 12.27 11.45 10.56
Enterprise Value to EBIT (EV/EBIT)		 49.34 89.49 139.97 73.21 86.06 41.13 20.91 16.07 18.49 16.76 15.38
Enterprise Value to NOPAT (EV/NOPAT)		 72.46 121.58 219.93 107.53 75.91 47.29 28.88 21.48 25.92 22.85 19.06
Enterprise Value to Operating Cash Flow (EV/OCF)		 29.43 30.22 34.99 22.69 20.65 14.88 11.60 10.25 14.67 13.94 10.86
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 67.19 35.92 21.98 87.55 49.14 75.30 64.28 15.05
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.10 0.11 0.11 0.11 0.11 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.10 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.19 -0.18 -0.18 -0.07 -0.08 -0.07 -0.04 -0.08 -0.13 -0.14 -0.12
Leverage Ratio		 1.23 1.22 1.21 1.26 1.26 1.21 1.20 1.20 1.21 1.15 1.15
Compound Leverage Factor		 1.11 1.56 1.15 1.25 1.31 1.23 1.21 1.21 1.23 1.19 1.20
Debt to Total Capital		 9.45% 9.76% 9.77% 9.70% 9.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 9.76% 9.77% 9.70% 9.59% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 9.45% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 90.55% 90.24% 90.23% 90.30% 90.41% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 1.13 1.05 0.87 0.69 0.71 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 -0.47 -0.15 -0.18 -0.43 -0.83 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 1.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 4.22 7.03 10.34 4.99 3.13 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 -1.78 -1.02 -2.17 -3.08 -3.62 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 4.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 5.05 5.27 6.51 6.84 7.39 10.95 8.52 7.99 11.00 11.32 10.39
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 4.88 2.33 2.42 2.51 2.54 4.45 4.07 4.13 4.26 4.56 4.62
Quick Ratio		 2.60 1.23 1.39 1.57 1.69 2.59 1.98 2.17 2.48 2.73 2.69
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -2,912 -2,925 -2,872 96 222 304 -98 -79 -139 -187 284
Operating Cash Flow to CapEx		 457.47% 183.38% 195.19% 485.45% 1,229.26% 491.09% 167.23% 697.14% 538.10% 510.83% 632.36%
Free Cash Flow to Firm to Interest Expense		 -1,128.09 -1,544.17 -1,230.10 124.25 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 40.56 27.66 23.24 262.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 31.69 12.58 11.33 208.65 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.44 0.54 0.62 0.47 0.49 0.52 0.53 0.54 0.56 0.61 0.60
Accounts Receivable Turnover		 4.38 5.02 5.25 4.58 4.75 4.70 4.29 4.59 4.75 5.08 4.82
Inventory Turnover		 0.96 1.26 1.63 1.28 1.37 1.34 1.27 1.29 1.35 1.39 1.25
Fixed Asset Turnover		 3.78 4.61 5.46 4.22 4.39 4.42 4.53 4.84 5.22 5.57 5.61
Accounts Payable Turnover		 11.82 15.92 17.87 14.36 15.71 16.01 12.68 13.26 11.01 11.27 10.20
Days Sales Outstanding (DSO)		 83.37 72.78 69.52 79.68 76.85 77.73 85.00 79.54 76.79 71.90 75.66
Days Inventory Outstanding (DIO)		 381.90 288.72 223.68 285.43 265.67 272.96 287.82 283.07 270.28 263.04 292.07
Days Payable Outstanding (DPO)		 30.89 22.93 20.42 25.41 23.23 22.80 28.78 27.52 33.15 32.38 35.80
Cash Conversion Cycle (CCC)		 434.38 338.57 272.78 339.70 319.29 327.89 344.04 335.09 313.93 302.55 331.93
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 3,822 3,861 3,886 3,800 3,664 3,627 4,066 3,992 3,944 3,933 3,928
Invested Capital Turnover		 0.66 0.79 0.92 0.65 0.67 0.67 0.66 0.71 0.77 0.82 0.79
Increase / (Decrease) in Invested Capital		 2,918 2,930 2,905 -53 -158 -234 180 192 280 306 -138
Enterprise Value (EV)		 7,167 7,330 9,160 9,417 10,750 9,607 7,761 7,328 11,056 10,854 9,885
Market Capitalization		 7,343 7,391 9,250 9,687 11,262 10,068 7,990 7,735 11,685 11,653 10,725
Book Value per Share		 $29.01 $28.98 $29.44 $30.05 $30.68 $29.72 $31.73 $32.57 $34.17 $34.99 $35.13
Tangible Book Value per Share		 $11.89 $11.70 $12.26 $13.26 $14.32 $13.69 $15.25 $16.22 $17.88 $19.02 $19.43
Total Capital		 4,415 4,346 4,407 4,507 4,621 4,088 4,296 4,399 4,573 4,732 4,769
Total Debt		 417 424 430 437 443 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 417 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -176 -62 -90 -270 -513 -461 -229 -407 -629 -799 -841
Capital Expenditures (CapEx)		 23 29 28 42 17 36 47 36 46 40 33
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 1,005 1,032 1,067 981 875 864 1,076 1,068 1,070 1,086 1,141
Debt-free Net Working Capital (DFNWC)		 1,523 1,466 1,560 1,676 1,765 1,325 1,305 1,458 1,627 1,716 1,736
Net Working Capital (NWC)		 1,523 1,042 1,130 1,238 1,321 1,325 1,305 1,458 1,627 1,716 1,736
Net Nonoperating Expense (NNE)		 -8.95 13 1.36 -8.12 38 -4.85 -121 -5.48 0.09 -5.29 -5.90
Net Nonoperating Obligations (NNO)		 -176 -62 -90 -270 -513 -461 -229 -407 -629 -799 -841
Total Depreciation and Amortization (D&A)		 132 116 124 134 122 72 77 78 76 70 69
Debt-free, Cash-free Net Working Capital to Revenue		 64.09% 54.35% 47.72% 39.57% 34.72% 34.42% 40.96% 38.55% 36.40% 35.02% 36.28%
Debt-free Net Working Capital to Revenue		 97.10% 77.24% 69.76% 67.60% 70.05% 52.79% 49.70% 52.65% 55.36% 55.33% 55.21%
Net Working Capital to Revenue		 97.10% 54.90% 50.51% 49.97% 52.45% 52.79% 49.70% 52.65% 55.36% 55.33% 55.21%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.02 ($0.05) $0.23 $0.38 $0.20 $0.55 $1.50 $0.88 $1.05 $0.92 $1.12
Adjusted Weighted Average Basic Shares Outstanding		 113.09M 135.36M 135.20M 135.62M 135.73M 136.76M 135.21M 134.50M 135.22M 135.36M 135.05M
Adjusted Diluted Earnings per Share		 $0.01 ($0.05) $0.23 $0.38 $0.19 $0.54 $1.49 $0.88 $1.01 $0.90 $1.10
Adjusted Weighted Average Diluted Shares Outstanding		 114.63M 135.36M 136.98M 138.06M 137.86M 139.77M 136.50M 135.39M 137.06M 138.19M 137.38M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 135.37M 135.06M 135.41M 136.17M 137.54M 135.38M 135.06M 133.84M 135.25M 135.74M 134.26M
Normalized Net Operating Profit after Tax (NOPAT)		 16 21 43 45 54 71 86 112 151 128 156
Normalized NOPAT Margin		 2.53% 3.41% 6.80% 7.12% 8.21% 11.93% 11.53% 14.50% 18.23% 16.87% 19.77%
Pre Tax Income Margin		 4.05% -1.41% 7.56% 9.11% 3.75% 17.33% 25.25% 18.72% 20.48% 20.67% 24.04%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 10.68 -3.52 21.38 74.59 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 2.36 2.96 14.19 56.41 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 1.82 -18.60 9.47 20.46 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 -6.51 -12.13 2.28 2.28 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 183.57% 463.59% 763.00% 339.13% 83.30% 103.97% 60.69% 60.52% 55.86% 18.75% 41.29%

Financials Breakdown Chart

Key Financial Trends

Globus Medical (NYSE: GMED) delivered a solid start to 2026, with revenue growth, strong profitability, and robust cash generation. Over the past four years, the company has shown meaningful top-line expansion, but results also reflect the impact of acquisitions, restructuring charges, and some volatility in working capital and debt.

What stands out most: GMED has grown from a company generating roughly $277 million in quarterly revenue in Q1 2023 to about $760 million in Q1 2026. At the same time, it has remained profitable and produced strong operating cash flow, which is a good sign for investors looking at long-term execution.

  • Revenue continues to scale: Q1 2026 revenue was $759.9 million, up from $598.1 million in Q1 2025 and well above $276.7 million in Q1 2023, showing strong multi-year growth.
  • Gross profit remains healthy: Q1 2026 gross profit of $525.8 million implies a strong gross margin profile, even with a sizable cost base.
  • Operating cash flow is strong: Q1 2026 operating cash flow reached $202.4 million, supporting the company’s ability to fund growth internally.
  • Balance sheet has strengthened versus early 2024: Total equity rose to $4.73 billion in Q1 2026 from $3.92 billion in Q1 2024, reflecting continued earnings retention and capital growth.
  • Liquidity is ample: The company ended Q1 2026 with $560.9 million in cash and equivalents plus $68.9 million in short-term investments.
  • Profitability improved sharply over the last two years: GMED went from a Q1 2024 loss of $7.1 million to Q1 2026 net income of $124.3 million.
  • EPS remains constructive: Q1 2026 diluted EPS was $0.90, versus $0.54 in Q1 2025 and a loss in Q1 2024.
  • Acquisitions remain part of the story: GMED spent $4.9 million on acquisitions in Q1 2026, following much larger acquisition activity in prior periods, suggesting ongoing portfolio expansion.
  • Investment activity is significant: The company purchased $146.4 million of investments in Q1 2026, which may help manage liquidity but also reduces cash temporarily.
  • Working capital remains a big investment: Inventories were $772.6 million and receivables were $686.4 million in Q1 2026, so a large amount of capital is tied up in operations.
  • Operating expenses remain heavy: Q1 2026 SG&A was $297.8 million, and total operating expenses were $375.4 million, which keeps pressure on margins despite strong revenue growth.
  • Restructuring charges have been recurring: GMED has reported restructuring charges in multiple periods, including $11.6 million in Q1 2026 and $11.9 million in Q4 2025, indicating ongoing integration or cost-reduction efforts.
  • Debt history was volatile: The company had meaningful short-term debt in 2024, including $437.1 million in Q3 2024, though debt appears to have been reduced or eliminated by 2025-2026.

Longer-term trend: GMED’s revenue growth has been impressive, especially after the 2024-2025 period when the company appears to have absorbed acquisitions and restructured operations. Revenue roughly doubled from early 2023 to early 2026, while net income also moved from volatile and sometimes negative results to consistently strong profitability.

Cash flow quality is a key strength. GMED has repeatedly generated positive operating cash flow, including $177.3 million in Q1 2025, $248.6 million in Q4 2025, and $202.4 million in Q1 2026. That gives the company flexibility to invest in CapEx, acquisitions, and share-related activity while maintaining a healthy cash position.

Investor takeaway: GMED looks like a company with strong growth momentum, good liquidity, and improving earnings power. The main things to watch are operating expense discipline, the pace of acquisition-driven growth, and whether restructuring charges eventually fade. If margins stay strong as revenue grows, the stock’s fundamental picture could remain attractive.

08/12/26 06:19 PM ETAI Generated. May Contain Errors.

Globus Medical Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Globus Medical's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Globus Medical's net income appears to be on an upward trend, with a most recent value of $537.87 million in 2025, rising from $112.78 million in 2015. The previous period was $102.98 million in 2024. See where experts think Globus Medical is headed by visiting Globus Medical's forecast page.

Globus Medical's total operating income in 2025 was $479.82 million, based on the following breakdown:
  • Total Gross Profit: $1.98 billion
  • Total Operating Expenses: $1.50 billion

Over the last 10 years, Globus Medical's total revenue changed from $544.75 million in 2015 to $2.94 billion in 2025, a change of 439.5%.

Globus Medical's total liabilities were at $729.51 million at the end of 2025, a 32.1% decrease from 2024, and a 514.2% increase since 2015.

In the past 10 years, Globus Medical's cash and equivalents has ranged from $0.00 in 2017 to $784.44 million in 2024, and is currently $526.16 million as of their latest financial filing in 2025.

Over the last 10 years, Globus Medical's book value per share changed from 7.51 in 2015 to 34.17 in 2025, a change of 355.0%.


Related Companies

Financial statements for NYSE:GMED last updated on 8/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Iran War: What Happened at 1:11 P.M. Outside D.C.?
A source with ties to Saudi Arabia, the UAE, and the U.S. State Department revealed details of a potential 7 t...
Banyan Hill Publishing | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
The government values gold at $42. It's really $4,800.
The U.S. Treasury still values its gold reserves at 42.22 dollars an ounce, a price set in 1973. Gold trades n...
Golden Portfolio | Sponsoredtc pixel
A $2 trillion fund just sounded the alarm
Norway's roughly $2 trillion sovereign wealth fund holds massive stakes in Nvidia, Apple and SpaceX. Its CEO n...
The Oxford Club | Sponsoredtc pixel